www.fdanews.com/articles/198444-takeda-to-commercialize-novavaxs-covid-19-vaccine-in-japan
Takeda to Commercialize Novavax’s COVID-19 Vaccine in Japan
August 10, 2020
Maryland-based Novavax has teamed up with Takeda Pharmaceutical Co. to commercialize Novavax’s COVID-19 vaccine candidate NVX-CoV2373 in Japan.
Under the agreement, Takeda will license and manufacture the vaccine with an adjuvant supplied by Novavax, producing more than 250 million vaccine doses per year if the vaccine is approved.
Takeda will be responsible for regulatory submissions and distribution in Japan.